Tilray (NASDAQ: TLRY) reports its Q1 FY2022 today, and investors expect EPS of -$0.07. Tilray stock price is under pressure this year, down significantly from the yearly highs.
Tilray produces and distributes medical cannabis products. The company is preparing to release its Q1 FY2022 results today, and investors expect EPS of $-0.07. In other words, the company is losing money, and the negative results are expected to continue in the quarters ahead.
Tilray stock price is down significantly from its yearly highs. In February this year, the stock price traded above $60, only to drop ever since.
The company does not pay a dividend since it is not making any profit at all. It operates with a gross profit margin of 24.01%, much lower than the 55.01% sector median.
Not Everyone Is Bearish on Tilray Stock Price
As the stock price comes close to $10, investors wonder if the stock is cheap enough to buy. Not everyone is bearish on Tilray stock price, at least if we judge by the number of analysts who cover the stock.
Five of the 20 analysts covering Tilray stock price have issued buy ratings, while 12 have issued neutral ratings. Only three analysts have a sell rating for the Tilray stock price.
Most recently, Cantor Fitzgerald maintained its buy rating for the Tilray stock price with a target of $18. At the same time, Tilray has recently completed its merger with Aphria and became the largest global cannabis producer.
The annual revenue estimates for the fiscal period ending March 2022 are projected at $796.66 million, and for the fiscal period ending March 2023, revenue is estimated to reach $970.90 million.